Sponsored Ultra-rapid Whole Genome Sequencing Offered for Select Critically Ill Infants

Updates from Rady Children's Institute for Genomic Medicine on rapid Whole Genome Sequencing and more.

Here at Rady Children’s Institute for Genomic Medicine, we are always looking for ways to make whole genome sequencing (WGS) available to more critically ill patients. That’s why we’re excited to announce our newest partnership with Inozyme Pharma to expand access to WGS.  

Inozyme is seeking patients with disease-causing variants in the ENPP1 and/or ABCC6 genes for possible participation in a clinical trial. Common presenting symptoms include: 

Chart displaying symptoms

Download the PDF flyer for more information. 

To help find those patients, Inozyme has offered to pay for ultra-rapid whole genome sequencing in critically ill babies who meet specific criteria.  

If you have a patient who you think qualifies for this sponsored testing, please contact us as soon as possible. We anticipate this opportunity to be available for the next 6-12 months, so even if you do not have a patient who meets criteria today, please keep this flyer available to refer to if a patient presents at a later date.  

Contact Us About BeginNGS